Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Cited by 12 Publications

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0832

PubMed: 31320594 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31270078 ( click the link to review the publication )

Cancer Lett, 2019, 445:34-44

PubMed: 30639533 ( click the link to review the publication )

Oncogenesis, 2019, 8(8):39

PubMed: 31311917 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Leukemia, 2018, 32(2):313-322

PubMed: 28895560 ( click the link to review the publication )

Cell Death Dis, 2018, 10(1):8

PubMed: 30584254 ( click the link to review the publication )

J Cell Physiol, 2018, 233(12):9437-9446

PubMed: 29968910 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35962-35973

PubMed: 30542510 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183161

PubMed: 28817624 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183161

PubMed: 28817624 ( click the link to review the publication )

Elife, 2014, 3

PubMed: 25531068 ( click the link to review the publication )

2 Customer Reviews

(f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.

Leukemia, 2018, 32(1):139-148. Midostaurin (PKC412) purchased from Selleck.

PKC412 is cytotoxic to human HNSCC cells. The established HNSCC cells (SQ20B and SCC‐9 cell lines), primary human oral carcinoma cells (“Primary1/2”) and primary oral epithelial cells (“Epithelial”), were treated with indicated concentrations of PKC412. Cells were then cultured in complete medium for the applied time, and cell survival was tested by the MTT assay (a, d) and colony formation assay (c). Cell death was tested by the trypan blue staining assay (b). “CTR” indicates medium‐treated control group (for all figures). All the experiments were repeated five times, and similar results were obtained. n = 5 for each assay. Error bars indicate mean ± SD (for all figures). *p < 0.05 versus group “CTR.” HNSCC, head and neck squamous cell carcinoma; MTT, 3‐(4,5‐dimethyl‐thiazol-2-yl)2,5-diphenyl tetrazolium bromide; OD, optical density; PKC, protein kinase C

J Cell Physiol, 2018, 233(12):9437-9446. Midostaurin (PKC412) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description

Targets

PKCα ^[1] (Cell-free assay)	PKCγ ^[1] (Cell-free assay)	PKCβ1 ^[1] (Cell-free assay)	PKCβ2 ^[1] (Cell-free assay)	PPK ^[1] (Cell-free assay)	View More
22 nM	24 nM	30 nM	31 nM	38 nM	View More

In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV4-11 cells	NUjRVGlQS3m2b4TvfIlkcXS7IHHzd4F6	M3LN[FczKGh?	MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?=	MV[xPVY2PDRyOB?=
RS4-11 cells	NHTWSmZHfW6ldHnvckBie3OjeR?=	Ml\qNkBp	MlO2TY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCUU{StNVEh[2WubIOgZYZ1\XJiMjDodpMh[nliZXzlZ5Rzd2OqZX3pcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyPUGzJI5O	MWWxPVY2PDRyOB?=
CGTH-W-1 cell	MnnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3LYXWlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Oi54NTFOwG0>	MULTRW5ITVJ?
SW982 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXTkfFMxUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjV6IN88US=>	MmnLV2FPT0WU
human EoL-1-cell cell	M4n6WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=>	M1TNOnNCVkeHUh?=
MOLM-13 cells	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmXHO\|IhcA>?	Ml3STY5pcWKrdHnvckBw\iCITGSzJGlVTCCqZYTldo97gWexdYOgcZV1[W62IHnuJIh2dWGwIF3PUG0uOTNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUCuNFU2KM7:TR?=	MlrSNlYxQDFyMkO=
KASUMI-1 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWLtWGlVUW6qaXLpeIlwdiCxZjDoeY1idiCNQWPVUWkuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwME[wNVYh\|ryP	MW\TRW5ITVJ?
NCI-H1755 cell	M2j3SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{G5cGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkK3N{DPxE1?	M3vuWXNCVkeHUh?=
human MES-SA cell	NXnQ[\|hWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFT5OVBKdmirYnn0bY9vKG:oIHj1cYFvKE2HUz3TRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODd3NESg{txO	NXjRZpB1W0GQR1XS
human HCC1395 cell	NU\sXoVzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYrN[mNCUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN\|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOESyPEDPxE1?	NYnHPI1rW0GQR1XS
human D-336MG cell	MkfxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=>	NFzwT5JUSU6JRWK=
CHP-212 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml\5TY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDd5MzFOwG0>	NIDzTplUSU6JRWK=
human KM12 cell	NGDjZXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4PiR2lvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNFkzPzVizszN	NI\Zc\|dUSU6JRWK=
A204 cell	M{jLRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVLnRZdoUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODB3MjFOwG0>	MW\TRW5ITVJ?
CAL-51 cell	NXLzVVJKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2nOS2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODdyOTFOwG0>	Mm\ZV2FPT0WU
human A431 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEj2fG5KdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjF4IN88US=>	NWDY[XhKW0GQR1XS
NCI-H650 cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUHoW4dEUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMUG3NFgh\|ryP	NVHoTY9TW0GQR1XS
A427 cell	M1Ltcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3[zUGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNVE6OThizszN	NH3lU4xUSU6JRWK=
human 769-P cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1TR[mlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=>	MomwV2FPT0WU
SW1710 cell	M2PKc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNVM{OTZizszN	NELz[VVUSU6JRWK=
human H4 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUfqS2s1UW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNVM6PjNizszN	NIrR[otUSU6JRWK=
HT-1080 cell	M3X5UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mmr2TY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTl6MjFOwG0>	MUnTRW5ITVJ?
human PANC-03-27 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNvMEOtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4MEKg{txO	MmLrV2FPT0WU
A375 cells	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=	NUXN[2tbPzJiaB?=	MXvUc5hq[2m2eTDh[4FqdnO2IHj1cYFvKEF\|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1yLkG4JO69VQ>?	MWmxPVY2PDRyOB?=
human HOP-62 cell	MnTVSpVv[3Srb36gZZN{[Xl?		Ml;2TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5ODd\|IN88US=>	M3nafXNCVkeHUh?=
human U031 cell	M4O0Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYnJcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5Olk5KM7:TR?=	MUTTRW5ITVJ?
mouse BAF3 cells	Mlq3VJJwdGmoZYLheIlwdiCjc4PhfS=>		NWKzdYhHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJJRz[W6\|Zn;ycYVlKHerdHigXm5HOTl6LV\HSnIyKGOxboP0dpVkfCxiSVO1NF0xNjJizszN	MXmyNVk{PjV2Mh?=
human G-402 cell	NGjIVotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIHORpVKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zODJ3MzFOwG0>	NWHZ[GpEW0GQR1XS
human G-361 cell	M4DldWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV3qSoJ1UW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB6NUOg{txO	M2OxcXNCVkeHUh?=
NCI-H810 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXXEcXByUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMkGwNlch\|ryP	Ml;WV2FPT0WU
NCI-H2030 cell	M2XNN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFvZN2VKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMkOwNFYh\|ryP	M1SweHNCVkeHUh?=
human HCT-116 cell	MnHIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PTZ6IN88US=>	MnPyV2FPT0WU
human SNU-423 cell	M1;PPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmWyTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0>	MWrTRW5ITVJ?
human SCC-4 cell	MnzlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYfS[olXUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN7Nkeg{txO	MV;TRW5ITVJ?
human SW48 cell	NEniW3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF;tNWZKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI3PjhizszN	NHjVbWVUSU6JRWK=
human SF295 cell	NELDSVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1ryfmlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4OjV5IN88US=>	MY\TRW5ITVJ?
MDA-MB-231 cell	NGjDU4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUnpU3Z7UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yPFExOSEQvF2=	M1PLZnNCVkeHUh?=
A172 cell	NHfGNIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUWwcI5mUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTF3IN88US=>	M1XBNXNCVkeHUh?=
human BCPAP cell	MmfBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6yPVg4QSEQvF2=	NISxc2RUSU6JRWK=
human COLO-792 cell	M3zhR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M37YVWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ7OUeyJO69VQ>?	M{fmWHNCVkeHUh?=
human DU-145 cell	M4j6OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2O1OWlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OTh6OTFOwG0>	Mn;uV2FPT0WU
NCI-H2122 cell	NVP5N\|F2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO	NX22dmRbW0GQR1XS
human SK-UT-1 cell	Ml\ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NU\3PZE4UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|Mkm1NkDPxE1?	MUHTRW5ITVJ?
LXF-289 cell	M2Dre2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH\hV2tKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OU[1JO69VQ>?	M3vhZnNCVkeHUh?=
human NCI-H1792 cell	M1PkNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{S4UWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|M{C5OkDPxE1?	MmexV2FPT0WU
MCF7 cell	M123dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWrDSIxFUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzJ5NDFOwG0>	MkXrV2FPT0WU
HCT-15 cell	NGfn[oZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3zwfGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR\|MjFOwG0>	MlHvV2FPT0WU
human NCI-H358 cell	NEnvSmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYG3d4x2UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFM2QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{O1OVEh\|ryP	NIHKTotUSU6JRWK=
human HLE cell	NGi0VHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{O3OVIh\|ryP	MWLTRW5ITVJ?
human SW1088 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFzLepdKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN5OUeg{txO	M2m5dnNCVkeHUh?=
human K5 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoLNTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwM{[xOFkh\|ryP	NF;FUmJUSU6JRWK=
human SR cell	NIDhVIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWjJcohq[mm2aX;uJI9nKGi3bXHuJHNTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|NkW3NUDPxE1?	MmmyV2FPT0WU
human Calu-3 cell	MojOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX;SV5cyUW6qaXLpeIlwdiCxZjDoeY1idiCFYXz1MVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN4OEK1JO69VQ>?	NVvGcZZLW0GQR1XS
human SK-MEL-30 cell	NV\rUVdvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3m3SWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|OUmxN{DPxE1?	M1f0U3NCVkeHUh?=
human SW780 cell	MmLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4PITGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyOTR{IN88US=>	NGTYW\|BUSU6JRWK=
NCI-H1563 cell	M{\adWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYHvXYs5UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?=	M4K3dXNCVkeHUh?=
human MKN45 cell	NGfiPZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkHZTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOFE6OzFizszN	MV7TRW5ITVJ?
MDA-MB-157 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR{MEG1JO69VQ>?	NWLyVYJ6W0GQR1XS
human NCI-H522 cell	NV7BSoVsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF\RZ3VKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO	M3fZTHNCVkeHUh?=
human A2780 cell	NF60TVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD60O\|UxOyEQvF2=	M2DvOHNCVkeHUh?=
human A498 cell	NYDEVGRoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3XQbWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOFc3QTNizszN	NV;DepNXW0GQR1XS
human BxPC-3 cell	NVOzO3VbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkS0TY5pcWKrdHnvckBw\iCqdX3hckBDgFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ6OzZ4IN88US=>	MmXYV2FPT0WU
human A2058 cell	NF\BZmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUTVd2pbUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ6NESg{txO	MkLkV2FPT0WU
human PC-14 cell	M2\MNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3H1d2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{QDV3IN88US=>	NWrYXHRyW0GQR1XS
human KG-1 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4XlTGlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOVU1OTlizszN	MnXMV2FPT0WU
human A375 cell	M3;aW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUnJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW2NVA{KM7:TR?=	Ml;yV2FPT0WU
human SW1783 cell	NYHRRWRXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH74eY5KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUe4N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzN\|NzFOwG0>	NEi1bmdUSU6JRWK=
human MKN1 cell	NGPufpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mny1TY5pcWKrdHnvckBw\iCqdX3hckBOU05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64PFQyOiEQvF2=	MXLTRW5ITVJ?
NCI-H1650 cell	NGrYfpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1;EWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OEmxOwOBiM7:TR?=	MU\TRW5ITVJ?
human HT-1376 cell	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIPqfmRKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGzO\|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl{OUG4JO69VQ>?	NWrkOGhUW0GQR1XS
SW872 cell	NVntU21PT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFfTWodKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0>	MWXTRW5ITVJ?
human RT-112 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGHzSYNKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd2OEOg{txO	MkXOV2FPT0WU
human HT-29 cell	NX3nTZk3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIn3TXFKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46Pzl7NjFOwG0>	MUDTRW5ITVJ?
human U-266 cell	NEL0[pBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXziZoR3UW6qaXLpeIlwdiCxZjDoeY1idiCXLUK2OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTh\|MEKg{txO	NFXNV5lUSU6JRWK=
human HEL cell	MorxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mnr3TY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4OVE4KM7:TR?=	NG\sNmZUSU6JRWK=
human KU812 cell	NVPrXGIzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUS4Snl1UW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTFzNkSg{txO	NHTTZm5USU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-TYR / p-STAT5 / STAT5 / p-S6 / S6 / p-MAPK / MAPK / p-AKT / AKT ; PubMed: 28881711 Oncotarget Effect of midostaurin and PRT062607 on TEL-SYK phosphorylation and phosphorylation of downstream effectors following 2 hr of treatment. For the experiment analyzing effects of midostaurin and PRT062607 on phosphorylation of TEL-SYK, SYK immunoprecipitation was carried out prior to immunoblotting with a PTYR (4G10) antibody. Immunoblotting was performed for the experiment analyzing effects of midostaurin and PRT062607 on signaling molecules downstream of TEL-SYK. Relative densitometry readings for pMAPK/total MAPK (normalized to control lane) are as follows: 0 nM midostaurin=1.0, 10 nM midostaurin=0.93, 100 nM midostaurin=0.41, 1000 nM midostaurin=0.04, 0 nM PRT062607=1.0, 10 nM PRT062607=0.72, 100 nM PRT062607=0.37, 1000 nM PRT062607=0.07. PKCα / PKCβ1 / PKCβ2 / PKCγ / PKCη / p-PKC / p-Bad / Bad / p-Bcl2 / Bcl-2 / p-p65 / p65; PubMed: 30584254 Cell Death Dis The indicated PKC isoforms were up-regulated in the resistant BL cells, leading to elevated levels of PKC phosphorylation and the activation of downstream anti-apoptotic proteins.	28881711 30584254

In vivo

Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. ^[1]

Protocol

Cell Research:^[2]	- Collapse Cell lines: A549, NCI-H520 Concentrations: ~1.0 μM Incubation Time: 24-72 h Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Colo 205 colorectal tumors xenograft Formulation: sterile water Dosages: 50 mg/kg, 200 mg/kg, once daily Administration: p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (175.24 mM)
	Ethanol	20 mg/mL warmed (35.04 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Midostaurin (PKC412) SDF

Molecular Weight	570.64
Formula	C₃₅H₃₀N₄O₄
CAS No.	120685-11-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CGP 41251

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04097470	Not yet recruiting	Drug: Decitabine\|Drug: Midostaurin	AML/MDS	Stichting Hemato-Oncologie voor Volwassenen Nederland\|Swiss Group for Clinical Cancer Research	September 16 2019	Phase 2
NCT03951961	Not yet recruiting	Drug: Midostaurin	Acute Myeloid Leukemia Adult	Sebastian Scholl PD Dr. med.\|Ludwig-Maximilians - University of Munich\|University of Jena	July 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PKC Signaling Pathway Map

Related PKC Products

SD-208 ^New

SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, >100-fold selectivity over TGF-βRII.
LDN-214117 ^New

LDN-214117 is a potent and selective BMP type I receptor kinase ALK2 inhibitor with IC50 of 24 nM.
Staurosporine

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Sotrastaurin

Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKCθ with K_i of 0.22 nM in a cell-free assay; inactive to PKCζ. Phase 2.

Features:Unlike former PKC inhibitors, Sotrastaurin does not enhance apoptosis of murine T-cell blasts in a model of activation-induced cell death.
Go 6983

Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKCζ and inactive to PKCμ.
Enzastaurin (LY317615)

Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.
Bisindolylmaleimide I (GF109203X)

Bisindolylmaleimide I (GF109203X) is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ in cell-free assays, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.

Features:Greater selectivity than PKC inhibitor staurosporine. GF109203X is a chemical probe for studying PKC signal transduction pathways. Potential for use in a variety of cancers.
Go6976

Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.
Bisindolylmaleimide IX (Ro 31-8220 Mesylate)

Bisindolylmaleimide IX (Ro 31-8220 Mesylate) is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.

Choose Your Country or Region

By Signaling Pathways

By product type

Midostaurin (PKC412)

Cited by 12 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Midostaurin (PKC412) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PKC Signaling Pathway Map

Related PKC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Midostaurin (PKC412)

Cited by 12 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Midostaurin (PKC412) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PKC Signaling Pathway Map

Related PKC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)